^
Association details:
| Biomarker: | BCR-ABL1 T315I |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | Nailike (olverembatinib) (Bcr-abl tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
EFFICACY AND SAFETY OF THE THIRD-GENERATION TKI OLVEREMBATINIB IN ADULTS PH/BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA WITH T315I MUTATION AND RELAPSED/REFRACTORY DISEASE
Published date:
05/11/2023
Excerpt:
By Jan. 15, 2023, the median follow-up time was 6 months (range, 1-10), and PFS and OS rates were 51.5% and64.5%....The novel third-generation TKI Olverembatinib is effective and safe in Chinese adult Ph/BCR-ABL1+ ALL with molecular or hematological R/R disease, especially in pts with T315I mutation.
